NCT03798509Unknown1 期
A Phase I Clinical Trial to Evaluate the Safety and Tolerability of Human CD19 Targeted T Cells Injection for Subjects With Relapsed and Refractory CD19-positive B-cell Acute Lymphoblastic Leukemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- DLT
研究概览
简要总结
To evaluate the safety and tolerance of human CD19 targeted T Cells injection for the treatment of relapsed and refractory CD19-positive B-cell acute lymphoblastic leukemia. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.
详细描述
Participants with relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia can participate if all eligibility criteria are met. Tests required to determine eligibility include disease assessments, a physical exam, electrocardiograph and blood draws. Participants receive chemotherapy prior to the infusion of CD19 CAR+ T cells. After the infusion, participants will be followed for side effects and effect of CD19 CAR+ T cells. Study procedures may be performed while hospitalized.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 to 70 Years Old, Male and female;
- •Expected survival > 12 weeks;
- •ECOG score 0-1;
- •Bone marrow examination clearly diagnosed as CD19 positive B-cell acute lymphoblastic leukemia and who met one of the following conditions:
- •Those who failed to achieve CR after at least 2 courses of standard chemotherapy or had early relapse after complete remission (<12 months) or late relapse after complete remission (≥ 12 months) and failed to achieve CR after 1 course of standard chemotherapy;
- •For Ph+ ALL: in addition to receiving at least 2 courses of standard chemotherapy, at least two TKIs should be treated with no complete remission or relapse after complete remission (Patients who cannot tolerate TKI therapy or have TKI treatment contraindications or have T315i mutation are excluded);
- •Those who relapse after stem cell transplantation are not affected by previous treatments;
- •The venous access required for collection can be established and mononuclear cell collection can be determined by the investigators;
- •Liver, kidney and cardiopulmonary functions meet the following requirements:
- •Creatinine is in the normal range;
- •Left ventricular ejection fraction >50%;
- •Baseline oxygen saturation>92%;
- •Total bilirubin ≤ 2×ULN; ALT and AST ≤2.5 × ULN;
- •Able to understand and sign the Informed Consent Document.
排除标准
- •Graft-versus-host disease (GVHD), or need to use immunosuppressants;
- •Malignant tumors other than acute lymphoblastic leukemia within 5 years prior to screening, in addition to adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical resection, and ductal carcinoma in situ after radical resection;
- •Subjects with positive HBsAg or HBcAb and peripheral blood HBV DNA titer detection ≥ 1 × 102 copy number / L; HCV antibody positive and peripheral blood HCV RNA positive; HIV antibody positive; CMV DNA positive; syphilis positive;
- •Any instability of systemic disease, including but not limited to unstable angina, cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York heart association (NYHA) classification ≥ III), need drug therapy of severe arrhythmia, liver, kidney, or metabolic disease;
- •Active or uncontrollable infection requiring systemic therapy within 14 days prior to enrollment;
- •Pregnant or lactating woman, and female subject who plans to have a pregnancy within 1 year after cell transfusion, or male subject whose partner plans to have a pregnancy within 1 year after cell transfusion;
- •Received CAR-T treatment or other gene therapies before enrollment;
- •Patients with symptoms of central nervous system;
- •Subjects who are receiving systemic steroid treatment and requiring long-term systemic steroid treatment during the treatment as determined by the investigator before screening (except inhalation or topical use); And subjects treated with systemic steroids (except inhalation or topical use) within 72h prior to cell transfusion;
- •The investigators consider other conditions unsuitable for enrollment.
研究组 & 干预措施
Human CD19 targeted T Cells Injection
Experimental
干预措施: Human CD19 targeted T Cells Injection (Drug)
结局指标
主要结局
DLT
时间窗: 28 days post infusion
次要结局
- Overall response rate (ORR) after administration(90 days post infusion)
- The immunogenicity of Human CD19 targeted T Cells Injection. (the detection of human anti-mouse antibody)(2 years post infusion)
- Duration of CAR-positive T cells in circulation(2 years post infusion)
- The concentration of CD19-positive B cells in peripheral blood.(2 years post infusion)
- Duration of remission (DOR) after administration(2 years post infusion)
- Progress Free Survival (PFS) after administration(2 years post infusion)
- Overall Survival (OS)after administration(2 years post infusion)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.CD19-positiveDiffuse Large B-cell LymphomaFollicular LymphomaNCT03720457Hrain Biotechnology Co., Ltd.18
尚未招募
1 期
To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.Acute Lymphoblastic LeukemiaNCT05223686Hrain Biotechnology Co., Ltd.18
招募中
2 期
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's LymphomaB-cell Non-Hodgkin's LymphomaNCT05436223Hrain Biotechnology Co., Ltd.100
尚未招募
1 期
CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell MalignanciesRelapsed/Refractory B-Cell MalignanciesNCT04943016National Taiwan University Hospital12
已完成
1 期
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid MalignanciesAcute Biphenotypic LeukemiaBlasts 5 Percent or More of Bone Marrow Nucleated CellsCD19 PositiveNon-Hodgkin LymphomaSmall Lymphocytic LymphomaStage III Chronic Lymphocytic LeukemiaStage IV Chronic Lymphocytic LeukemiaAcute Lymphoblastic LeukemiaMinimal Residual DiseaseNCT02529813M.D. Anderson Cancer Center26